TITLE

Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2)

AUTHOR(S)
Giorgino, Francesco; Benroubi, Marian; Jui-Hung Sun; Zimmermann, Alan G.; Pechtner, Valeria; Sun, Jui-Hung
PUB. DATE
December 2015
SOURCE
Diabetes Care;Dec2015, Vol. 38 Issue 12, p2241
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
Objective: This study compared the efficacy and safety of once-weekly dulaglutide, a glucagon-like peptide-1 receptor agonist, with daily insulin glargine, both combined with maximally tolerated doses of metformin and glimepiride in patients with type 2 diabetes. The primary objective was noninferiority of dulaglutide 1.5 mg to glargine in the HbA1c change from baseline at 52 weeks.Research Design and Methods: In this 78-week, open-label study, 810 patients were randomized to dulaglutide 1.5 mg, dulaglutide 0.75 mg, or glargine.Results: The baseline mean ± SD HbA1c was 8.1 ± 1.0% (65.5 ± 10.8 mmol/mol). The least squares mean ± SE HbA1c change from baseline to the primary end point was -1.08 ± 0.06% (-11.8 ± 0.7 mmol/mol) for dulaglutide 1.5 mg, -0.76 ± 0.06% (-8.3 ± 0.7 mmol/mol) for dulaglutide 0.75 mg, and -0.63 ± 0.06% (-6.9 ± 0.7 mmol/mol) for glargine, with an end point mean ± SD dose of 29 ± 26 units (0.33 ± 0.24 units/kg), and a fasting plasma glucose (mean ± SD) of 118 ± 23 mg/dL from self-monitored plasma glucose. Statistical criteria for superiority were met with dulaglutide 1.5 mg and for noninferiority with dulaglutide 0.75 mg. More patients on dulaglutide 1.5 mg achieved HbA1c targets <7.0% (53 mmol/mol) versus glargine (P < 0.001). Body weight decreased with dulaglutide and increased with glargine. Total hypoglycemia rates were lower with dulaglutide; severe hypoglycemia was minimal. Increases in pancreatic enzymes were observed for dulaglutide. Incidence of nausea (15.4, 7.7, and 1.5%) and diarrhea (10.6, 9.2, and 5.7%) were more common with dulaglutide 1.5 mg and 0.75 mg than with glargine.Conclusions: Once-weekly dulaglutide 1.5 mg, compared with daily insulin glargine without forced titration, demonstrated greater HbA1c reduction and weight loss, with a higher incidence of gastrointestinal adverse events and a lower risk of hypoglycemia.
ACCESSION #
111188637

 

Related Articles

  • Clinical potential of liraglutide in cardiovascular risk reduction in patients with type 2 diabetes: evidence to date. Howell, Rebecca; Wright, Adrienne M; Clements, Jennifer N // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;Apr2019, Vol. 12, p505 

    Metformin is the first-line therapy for the management of type 2 diabetes. After 3 months of metformin, add-on therapy can be considered if an individual's glycemic control has not been achieved for hemoglobin A1c, fasting blood glucose levels, and postprandial blood glucose levels. Liraglutide...

  • Management of Blood Glucose in Type 2 Diabetes Mellitus. RIPSIN, CYNTHIA M.; KANG, HELEN; URRBAN, RANDDALL J. // American Family Physician;1/1/2009, Vol. 79 Issue 1, p29 

    Evidence-based guidelines for the treatment of type 2 diabetes mellitus focus on three areas: intensive lifestyle intervention that includes at least 150 minutes per week of physical activity, weight loss with an initial goal of 7 percent of baseline weight, and a low-fat, reduced-calorie diet;...

  • Controlling diabetes.  // Mayo Clinic Health Letter;Sep2014, Vol. 32 Issue 9, p1 

    The article discusses how to control the disease called diabetes, particularly Type 1 and type 2 diabetes. It cites the importance of controlling blood glucose levels in the long term because extra glucose in the bloodstream will result in such ailments as heart disease, kidney disease, and eye...

  • New strategy for the treatment of type 2 diabetes mellitus with incretin-based therapy. Namba, Mitsuyoshi; Katsuno, Tomoyuki; Kusunoki, Yoshiki; Matsuo, Toshihiro; Miuchi, Masayuki; Miyagawa, Jun-ichiro // Clinical & Experimental Nephrology;Feb2013, Vol. 17 Issue 1, p10 

    Incretin-based therapy was first made available for the treatment of type 2 diabetes mellitus (T2DM) in the US in 2006 and in Japan in 2009. Four DPP-4 inhibitors and two GLP-1 analog/receptor agonists are currently available. The effects of incretin-based therapy are assumed to be exerted...

  • Improved Glycaemia Correlates with Liver Fat Reduction in Obese, Type 2 Diabetes, Patients Given Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists. Cuthbertson, Daniel J.; Irwin, Andrew; Gardner, Chris J.; Daousi, Christina; Purewal, Tej; Furlong, Niall; Goenka, Niru; Louise Thomas, E.; Adams, Valerie L.; Pushpakom, Sudeep P.; Pirmohamed, Munir; Kemp, Graham J. // PLoS ONE;Dec2012, Vol. 7 Issue 12, p1 

    Glucagon-like peptide-1 receptor agonists (GLP-1 RA) are effective for obese patients with type 2 diabetes mellitus (T2DM) because they concomitantly target obesity and dysglycaemia. Considering the high prevalence of non-alcoholic fatty liver disease (NAFLD) in patients with T2DM, we determined...

  • Efficacy and safety profile of once-weekly dulaglutide in type 2 diabetes: a report on the emerging new data. Kugler, Anne J; Thiman, Michael L // Diabetes, Metabolic Syndrome & Obesity: Targets & Therapy;May2018, Vol. 11, p187 

    Dulaglutide is a once-weekly glucagon-like peptide-1 receptor agonist, which has been on the market in the USA since 2014. Dulaglutide has performed well in head-to-head studies against metformin, glargine, and sitagliptin, where its A1c lowering ranged from -0.78% to –1.64% over...

  • Polymorphisms of GLP-1 Receptor Gene and Response to GLP-1 Analogue in Patients with Poorly Controlled Type 2 Diabetes. Lin, Chia-Hung; Lee, Yun-Shien; Huang, Yu-Yao; Hsieh, Sheng-Hwu; Chen, Zih-Syuan; Tsai, Chi-Neu // Journal of Diabetes Research;2/15/2015, Vol. 2015, p1 

    Aim. The relationship between genetic polymorphisms of the glucagon-like peptide-1 (GLP-1) receptor (GLP1R) gene and unresponsiveness to GLP-1 analogue treatment in patients with poorly controlled type 2 diabetes mellitus (DM) is unclear. Methods. Thirty-six patients with poorly controlled type...

  • Sulfonylurea versus metformin in type 2 diabetes.  // CMAJ: Canadian Medical Association Journal;10/7/2014, Vol. 186 Issue 14, p1067 

    The article focuses on a study of patient-important outcomes by comparing sulfonylurea and metformin monotherapy in patients with type 2 diabetes. It noted some effects of sulfonylurea including a decline in the risk of nonfatal macrovascular outcomes and the development of mild and severe...

  • Pramlintide Improved Glycemic Control and Reduced Body Weight in Patients With Type 2 Diabetes Treated With Basal Insulin (Without Mealtime Insulin) and a Thiazolidinedione. Lorenzi, Gayle; Frias, Juan; Lutz, Karen; Kesty, Nicole; Zhang, Bei; Kolterman, Orville // Diabetes;Jun2007 Supplement 1, Vol. 56, pA147 

    Pramlintide (PRAM), an analog of the β-cell hormone amylin, improves glycemic control and body weight in patients with type 2 diabetes (T2DM) treated with insulin with or without sulfonylurea (SFU) and/or metformin (MET). Its efficacy and safety as an adjunct to insulin+thiazolidinedione...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics